NO20052943L - Fremgangsmate for beskyttelse mot stralingsskade ved hjelp av alfa-tymosin - Google Patents

Fremgangsmate for beskyttelse mot stralingsskade ved hjelp av alfa-tymosin

Info

Publication number
NO20052943L
NO20052943L NO20052943A NO20052943A NO20052943L NO 20052943 L NO20052943 L NO 20052943L NO 20052943 A NO20052943 A NO 20052943A NO 20052943 A NO20052943 A NO 20052943A NO 20052943 L NO20052943 L NO 20052943L
Authority
NO
Norway
Prior art keywords
alpha
thymosin
protecting against
radiation damage
against radiation
Prior art date
Application number
NO20052943A
Other languages
English (en)
Other versions
NO20052943D0 (no
NO330217B1 (no
Inventor
Alfred R Rudolph
Cynthia W Tuthill
Original Assignee
Sciclone Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciclone Pharmaceuticals Inc filed Critical Sciclone Pharmaceuticals Inc
Publication of NO20052943D0 publication Critical patent/NO20052943D0/no
Publication of NO20052943L publication Critical patent/NO20052943L/no
Publication of NO330217B1 publication Critical patent/NO330217B1/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57581—Thymosin; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/16—Emollients or protectives, e.g. against radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20052943A 2002-11-25 2005-06-16 Alfa-tymosinpeptid for beskyttelse av celler mot stralingsskade. NO330217B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US42874602P 2002-11-25 2002-11-25
PCT/US2003/037469 WO2004048971A1 (en) 2002-11-25 2003-11-25 Methods of protecting against radiation damage using alpha thymosin

Publications (3)

Publication Number Publication Date
NO20052943D0 NO20052943D0 (no) 2005-06-16
NO20052943L true NO20052943L (no) 2005-08-09
NO330217B1 NO330217B1 (no) 2011-03-07

Family

ID=32393452

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052943A NO330217B1 (no) 2002-11-25 2005-06-16 Alfa-tymosinpeptid for beskyttelse av celler mot stralingsskade.

Country Status (16)

Country Link
US (1) US7897567B2 (no)
EP (1) EP1570269B1 (no)
JP (1) JP2006507349A (no)
KR (1) KR20050086819A (no)
CN (1) CN100501400C (no)
AT (1) ATE511852T1 (no)
AU (1) AU2003295838B2 (no)
BR (2) BR0316646A (no)
CA (1) CA2506893A1 (no)
EA (1) EA008059B1 (no)
MX (1) MXPA05005538A (no)
NO (1) NO330217B1 (no)
NZ (1) NZ540847A (no)
PL (1) PL377376A1 (no)
UA (1) UA81932C2 (no)
WO (1) WO2004048971A1 (no)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100311656A1 (en) * 2003-04-23 2010-12-09 Sciclone Pharmaceuticals, Inc. Treatment or prevention of respiratory viral infections with alpha thymosin peptides
JP2007523878A (ja) * 2003-07-18 2007-08-23 リジェナークス・バイオファーマスーティカルズ・インコーポレイテッド 放射線被曝による損傷の処置または防止
CN101443080B (zh) * 2006-03-07 2015-01-14 比奥滕普特公司 肽在控制辐射损伤中的用途
US20140213506A1 (en) * 2011-02-09 2014-07-31 Cynthia W. TUTHILL Thymosin alpha peptide for preventing, reducing the severity of, and treating infection
US20130296223A1 (en) * 2012-03-30 2013-11-07 Sciclone Pharmaceuticals, Inc. Use of thymosin alpha for the treatment of sepsis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1195980A (en) 1966-08-24 1970-06-24 Univ Yeshiva Hormone-Like Preparations Derived from Thymus Gland and Methods of Producing the Same.
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4079127A (en) * 1976-10-28 1978-03-14 Board Of Regents Of The University Of Texas Thymosin alpha 1
US4116951A (en) 1977-04-22 1978-09-26 Hoffmann-La Roche Inc. [Asn2 ]-thymosin α1 and analogs thereof
US4148788A (en) 1978-01-23 1979-04-10 Hoffmann-La Roche Inc. Synthesis of thymosin α1
DE2919592A1 (de) * 1979-05-15 1981-01-15 Max Planck Gesellschaft Verfahren zur herstellung von thymosin- alpha 1 und derivaten davon
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US4917888A (en) 1985-06-26 1990-04-17 Cetus Corporation Solubilization of immunotoxins for pharmaceutical compositions using polymer conjugation
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
CN1094310A (zh) 1992-12-15 1994-11-02 托马斯·C·梅里根 人体免疫缺陷性病毒感染用组合式化学疗法
CN1058500C (zh) * 1993-02-03 2000-11-15 施塞克龙药品公司 胸腺素α－1衍生物
TW252045B (no) * 1993-10-07 1995-07-21 Allan L Goldstein
ATE214940T1 (de) 1993-11-10 2002-04-15 Enzon Inc Verbesserte interferon-polymerkonjugate
US5908621A (en) 1995-11-02 1999-06-01 Schering Corporation Polyethylene glycol modified interferon therapy
US6197751B1 (en) * 1997-11-10 2001-03-06 The United States Of America As Represented By The Department Of Health And Human Services Thymosin α1 promotes tissue repair, angiogenesis and cell migration
US6309633B1 (en) * 1999-06-19 2001-10-30 Nobex Corporation Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same
CN1303713A (zh) 2000-01-07 2001-07-18 广州暨南大学医药生物技术研究开发中心 预防和治疗辐射损伤的保健组合物
US6462017B1 (en) * 2000-05-01 2002-10-08 Sciclone Pharmaceuticals, Inc. Method of reducing side effects of chemotherapy in cancer patients
CN1507357A (zh) 2000-10-31 2004-06-23 PRҩƷ���޹�˾ 提高生物活性分子传递的方法和组合物
UA80957C2 (en) * 2001-11-01 2007-11-26 Sciclone Pharmaceuticals Inc Method of administering a thymosin alpha 1 peptide
UA78726C2 (en) * 2001-11-01 2007-04-25 Sciclone Pharmaceuticals Inc Pharmaceutical composition of thymosin alpha 1 conjugated with polyethylene glycol, method for production, and method for treatment

Also Published As

Publication number Publication date
EP1570269A4 (en) 2008-09-10
BR0316646A (pt) 2005-10-11
EA200500773A1 (ru) 2005-12-29
NZ540847A (en) 2006-07-28
EA008059B1 (ru) 2007-02-27
CN1717587A (zh) 2006-01-04
WO2004048971A1 (en) 2004-06-10
KR20050086819A (ko) 2005-08-30
UA81932C2 (uk) 2008-02-25
US20060166877A1 (en) 2006-07-27
PL377376A1 (pl) 2006-02-06
US7897567B2 (en) 2011-03-01
EP1570269B1 (en) 2011-06-08
AU2003295838A1 (en) 2004-06-18
AU2003295838B2 (en) 2008-05-22
BRPI0316646A8 (pt) 2018-04-24
ATE511852T1 (de) 2011-06-15
NO20052943D0 (no) 2005-06-16
EP1570269A1 (en) 2005-09-07
MXPA05005538A (es) 2005-08-16
JP2006507349A (ja) 2006-03-02
CA2506893A1 (en) 2004-06-10
CN100501400C (zh) 2009-06-17
NO330217B1 (no) 2011-03-07

Similar Documents

Publication Publication Date Title
AR031614A1 (es) Sistema y metodo para prevenir y/o reducir la corrosion en diversos articulos
YU30700A (sh) Kombinacija inhibitora aldozo reduktaze i inhibitora glikogen fosforilaze
EA200400966A1 (ru) Новые лекарственные формы замещенного бензимидазола и способ их применения
HRP20050436B1 (hr) Kinolinil-pirolpirazoli
NO20054369L (no) Anvendelse av en IBAT-inhibitor for behandling og profylakse av forstoppelse
EA199901115A1 (ru) Композиции и способы ингибирования фотостарения кожи
DK0918504T3 (da) Anvendelse af genistein som et forebyggende middel mod af ultraviolet stråling induceret hudfotobeskadigelse og cancer.
NO20050537L (no) Anvendelse av HMGB1 i behandlingen av vevsskade og/eller for a fremme vevsreparasjon
WO2003020202A3 (en) Method for reducing hypertension and heart failure
WO2003088906A3 (en) Methods of simultaneously treating ocular rosacea and acne rosacea
DE60327557D1 (de) Verwendung von spongosin (2-methoxyadenosin) zur behandlung von schmerzen, insbesondere hyperalgesie
EA200601079A1 (ru) Способы защиты от радиации с использованием флагеллина
RU94044453A (ru) Применение 2-фенил-3-ароилбензотиофенов для ингибирования себореи и угрей
NO20052943D0 (no) Fremgangsmate for beskyttelse mot stralingsskade ved hjelp av alfa-tymosin
DE69433685D1 (de) Unterdrückung von inhibitoren
DK0892633T3 (da) Anvendelse af inhibitorer af aktiviteten af retinsyre til at behandle følsom hud og/eller akutte skader induceret af UV-stråling
BR9711057A (pt) M-todo para aumentar a efic cia de um composto antifÚngio usado para tratar uma infec-Æo fÚngica m-todo para tratar uma infec-Æo fÚngica composi-Æo farmaceutica e m-todo para controlar o crescimento de um organismo fungico em um substrato a ser inserido no corpo
DK1509523T3 (da) Triazaspiro-forbindelser anvendelige for at behandle eller forhindre smerte
NO20051681L (no) Lysaldring av hud og aktinskadebehandling
ATE396718T1 (de) Zusammensetzungen und verfahren zur behandlung von hepatitis-c-virus (hcv) infektion
DE60325904D1 (de) Kosmetische und/oder pharmazeutische zubereitung eür die behandlung und die prävention von reizungen, entzündungen und hauterythema
DE50210987D1 (de) Verbindungen zur beseitigung und/oder linderung der anhedonie
NO20054912D0 (no) Behandling av aspergillus infeksjoner med tymosin alfa 1
UA83628C2 (ru) Способ защиты эндотелиальных и эпителиальных клеток во время трансплантации алогенных стволовых клеток
ES2193285T3 (es) Inhibidor de oxido nitrico (no)-sintasa para prevenir la diabetes de tipo ii.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees